Mississippi will receive $18.5 million from Indianapolis-based drugmaker Eli Lilly and Co. as part of a settlement over claims
the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat.
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
Analysts worry about dive in already paltry sales of new blood thinner Effient
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local
airport facility.
Express Scripts Inc. on the west side of Indianapolis and Zipp Speed Weaponry in Speedway are scheduled Wednesday afternoon
to announce the
creation of hundreds of new jobs.
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune
diseases.
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Two semi-trailers of the medication were stolen in 2007 from a back lot at Daum Trucking, which isn’t named in the lawsuit.
Bristol-Myers charges MD Logistics with negligence in the $10.7 million suit.
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
